| abstract |
Compounds of formula (I), wherein B is O or CH2; X is selected from NR<1>R<2>, SR<1>, and C1-C7 alkyl; Y is selected from SR<1>NR<1>R<2>, and C1-C7 alkyl; R<1> and R<2> are each and independently selected from H, or C1-C7 alkyl optionally substituted upon or within the alkyl chain by one or more of O, S, N or halogen; R<3> and R<4> are both H, <u>or</u> R<3> and R<4> together form a bond; A is COOH, C(O)NH(CH2)pCOOH, C(O)N[(CH2)qCOOH]2; C(O)NHCH(COOH)(CH2)rCOOH, <u>or</u> 5-tetrazolyl, wherein p, q and r are each and independently 1, 2, or 3; as well as pharmaceutically acceptable salts and prodrugs thereof, pharmaceutical compositions comprising the novel compounds and use of the compounds in therapy. Also within the scope of the invention are novel intermediates to the novel compounds. The novel compounds are in particular useful in the prevention of platelet aggregation. |